2022 Mo-99 TOPICAL MEETING

CURIUM Mo-99 SUPPLY UPDATE

Roy W. Brown
V.P., Government Affairs & Strategic Alliances
June 22, 2022

OVERVIEW OF CURIUM OPERATIONS

- Molybdenum (Mo-99) facility in Petten makes Curium the only global vertically integrated SPECT manufacturer
  - Very high reliability for the key isotope used in c.80% of all nuclear medicine procedures
- Leading SPECT manufacturing footprint with three Tc-99m generator facilities, 2 in Europe and 1 in the U.S.
- 10 High Energy Cyclotrons across the network enabling a broad offering of complex medical isotopes.
- 70 MeV cyclotron in Noblesville, IN.
- Delivering SPECT products to >60 countries worldwide
- 23 SPECT/26 PET radipharmacies across Europe dispensing unit doses.
- 50+ products in portfolio for a wide diversity of medical applications (e.g. cardiovascular, oncology, bone).



CURIUM'S LEU CONVERSION EFFORT

- Curium began it's HEU to LEU conversion effort in 2010.
- That conversion was completed, and we converted to 100% LEU targets in January of 2018.
- Later in 2018 we added the production of LEU-based Xe-133 production.
- We appreciate the technical and financial assistance provided by the U.S. Department of Energy during our conversion effort.



CURIUM™
LIFE FORWARD

FOR IMMEDIATE RELEASE January 16, 2018

Curium Is the First North American Manufacturer Offering Exclusively 100% LEU Generators

(St. Louis - January 16, 2018) — Curium, a leading nuclear medicine solutions provider, announced today that the company is the first North American manufacturer to meet the deadline established by the American Medical Isotope
2012. This legislation effectively mandates the full conversion
enriched uranium (HEU) as soon as possible and no later than
multi-year project to transition its molybdenum-99 (Mo-99) proc
to low enriched uranium (LEU) was completed in late-2017. Th
the only North American Technetium Tc 99m Generator manuf
customers exclusively with 100 percent LEU Tc 99m generator
isotope of Tc 99m, which is used in 30 to 40 million nuclear me
worldwide every year[1].

Curium is the world's largest supplier of Tc 99m generators and
99 in the world. "This milestone helps satisfy the goals set forth
Energy's (DOE) National Nuclear Security Administration (NNS
support for the NNSA project to eliminate the use of weapons-g
production of medical isotopes. We are eager to see others fol
with the government's call for full conversion as soon possible"
American CEO, Dan Brague.

This project is the culmination of more than seven years of wor
collaboration with Curium's irradiation partners: the Dutch High
MARIA reactor, and BR2 in Belgium, as well as, the DOE and
President, Government Affairs for Curium North America, state
conversion helps Curium generator customers eliminate the in
availability of both HEU and LEU generators in their inventory
costs better. Something that is especially important when you
reimbursement guidelines surrounding LEU versus HEU patien

CURIUM™
LIFE FORWARD

FOR IMMEDIATE RELEASE May 10, 2018

Curium Expands Nuclear Medicine Offerings, Announces U.S. Availability of Xenon Xe 133 Gas

(St. Louis – May 10, 2018) — Curium, a leading nuclear medicine solutions provider, announced today its re-entry into the radiopharmaceutical Xenon Xe 133 Gas market, expanding the company's offerings to meet the needs of U.S. nuclear medicine patients. The bulk Xenon Xe 133 used in production is sourced from Curium's Petten manufacturing facility, using Low Enriched Uranium (LEU) targets. Curium's multi-year project to transition its molybdenum-99 (Mo-99) processing facility from Highly Enriched Uranium (HEU) to LEU was completed in late-2017. By sourcing the bulk Xenon Xe 133 material from LEU targets used in the Petten facility, Curium has created a vertically integrated supply chain that provides additional control over the manufacturing process and ensures product availability.

"We are pleased to provide our customers with a choice when selecting Xenon Xe 133 Gas to help diagnose patient disease for approved indications," said Curium North American CEO, Dan Brague. "As a global leader in nuclear medicine, Curium's commitment to the industry is evidenced by our ongoing investments in our product portfolio, including making Xenon Xe 133 Gas available to clinicians across the U.S., with a focus on reliable, long-term supply."

Radiopharmaceuticals are products that can be used in conjunction with gamma cameras for nuclear medicine procedures to help physicians find and diagnose certain diseases or study the function of the body's organs. Xenon Xe 133 Gas, approved by the U.S. Food and Drug Administration, has been shown to be valuable for diagnostic inhalation studies for the evaluation of pulmonary function, for imaging the lungs and may also be applied to assessment of cerebral blood flow.

Orders for Xenon Xe 133 Gas from Curium may be placed effective immediately.

OTHER RECENT DEVELOPMENTS AT CURIUM



CURIUM™
LIFE FORWARD

FOR IMMEDIATE RELEASE August 24, 2021

Curium Announces Submission of an Investigational New Drug (IND) Application for Cu-64 PSMA I&T

(ST. LOUIS, MO – August 24, 2021) – Curium announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for Cu-64 PSMA I&T, a radiopharmaceutical that binds to Prostate-Specific Membrane Antigen (PSMA) for use with Positron Emission Tomography (PET), for the detection and localization of metastatic prostate cancer. If approved, Curium expects that its Cu-64 PSMA I&T would be the first Cu-64 PSMA I&T agent for imaging of prostate cancer available in the U.S. With the benefit of Cu-64's 12.7-hour half-life, Curium has the ability to manufacture Cu-64 products centrally at its Maryland Heights, Missouri facility and distribute throughout the U.S. The unique properties of Cu-64 would allow access to PSMA-based prostate cancer imaging in the PET modality to all U.S. imaging sites without local cyclotron production or access to a nearby gallium generator.

"We are excited about advancing Cu-64 PSMA to the clinical trial stage and advancing Curium's copper-based radiopharmaceutical imaging platform. The imaging market has broadly adopted our recently approved Cu-64 imaging agent," said Curium Interim CEO, North America, Mike Patterson. "If approved, a Cu-64 PSMA imaging agent would bring unique attributes to the prostate cancer imaging market, including easy access to the product, convenience, and flexibility."

"We are committed to working closely with the FDA to potentially bring a new radiopharmaceutical imaging agent to patients and their healthcare professionals in the imaging of prostate cancer using PET," said Curium Vice President of Medical and Compliance, Ed Porter. "We look forward to engaging additional clinical trial sites as we finalize our clinical development program."

About Curium

Curium is the world's largest nuclear medicine company. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

OTHER RECENT DEVELOPMENTS AT CURIUM



CUR
LIFE

FOR IMMEDIATE RELEASE

Curium Announces Submission of an Investigat Drug (IND) Application for Cu-64 PSMA I&T

(ST. LOUIS, MO – August 24, 2021) – Curium announced today that it has Investigational New Drug (IND) application to the U.S. Food and Drug Adm Cu-64 PSMA I&T, a radiopharmaceutical that binds to Prostate-Specific Me (PSMA) for use with Positron Emission Tomography (PET), for the detectio metastatic prostate cancer. If approved, Curium expects that its Cu-64 PSM first Cu-64 PSMA I&T agent for imaging of prostate cancer available in the of Cu-64's 12.7-hour half-life, Curium has the ability to manufacture Cu-64 its Maryland Heights, Missouri facility and distribute throughout the U.S. Th of Cu-64 would allow access to PSMA-based prostate cancer imaging in th U.S. imaging sites without local cyclotron production or access to a nearby

"We are excited about advancing Cu-64 PSMA to the clinical trial stage anc copper-based radiopharmaceutical imaging platform. The imaging market h our recently approved Cu-64 imaging agent," said Curium Interim CEO, No Patterson. "If approved, a Cu-64 PSMA imaging agent would bring unique prostate cancer imaging market, including easy access to the product, conv flexibility."

"We are committed to working closely with the FDA to potentially bring a ne radiopharmaceutical imaging agent to patients and their healthcare profess of prostate cancer using PET," said Curium Vice President of Medical and Porter. "We look forward to engaging additional clinical trial sites as we fina development program."

About Curium

Curium is the world's largest nuclear medicine company. We develop, man distribute world-class radiopharmaceutical products to help patients around proven heritage combined with a pioneering approach are the hallmarks to excellence, and unparalleled service.

CURIUM™
LIFE FORWARD

FOR IMMEDIATE RELEASE October 27, 2021

Curium Initiates ECLIPSE, a Phase 3 Clinical Trial For Its Investigational Lu 177 PSMA I&T

(ST. LOUIS, MO – October 27, 2021) – Curium announced today that the Company has received a Study May Proceed letter from the U.S. Food and Drug Administration (FDA) to begin its Phase 3 trial with its investigational product lutetium Lu 177 PSMA I&T, a therapeutic radiopharmaceutical that binds to the Prostate-Specific Membrane Antigen (PSMA) protein. Curium is working closely with sites across the U.S. to initiate the ECLIPSE trial (A Multi-Center, Open-Label, Randomized Phase 3 Trial Comparing the Safety and Efficacy of 177Lu-PSMA-I&T versus Hormone Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer).

If approved, Curium expects to manufacture the product in its Noblesville, Indiana facility, leveraging its centralized production capabilities and logistical expertise. "We are excited about advancing Lu 177 PSMA I&T to the clinical trial stage, particularly in light of our recent announcement for our Cu 64 PSMA I&T imaging agent. We believe this represents an exciting opportunity for patients nationwide and their healthcare providers," said Curium CEO, North America, Mike Patterson.

"We are committed to working closely with the FDA to potentially bring this new therapeutic radiopharmaceutical agent to patients and their healthcare professionals," said Curium Vice President of Medical and Compliance, Ed Porter. "We look forward to engaging additional clinical trial sites as we finalize our clinical development program."

About Curium

Curium is the world's largest nuclear medicine company. We develop, manufacture, and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence, and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for potentially life-threatening diseases to over 14 million patients annually. The name 'Curium' honors the legacy of pioneering radioactive researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine.

To learn more, visit www.curiumpharma.com. For more information about this press release, please contact Janet Ryan, media contact for Curium: janet@ryan-pr.com.

OTHER RECENT DEVELOPMENTS AT CURIUM



FOR IMMEDIATE

Curium Ann
Drug (IND) A

(ST. LOUIS, MO – Investigational New Cu-64 PSMA I&T, a (PSMA) for use with metastatic prostate first Cu-64 PSMA I of Cu-64's 12.7-hou its Maryland Height of Cu-64 would allo U.S. imaging sites

"We are excited ab copper-based radio our recently approv Patterson. "If appr prostate cancer ima flexibility."

"We are committed radiopharmaceutica of prostate cancer Porter. "We look fo development progr

About Curium

Curium is the world distribute world-cla proven heritage co excellence, and un

FOR IMMEDIATE RELEASE

Curium Initiates ECLIPSE, a Investigational Lu 177 PSMA

(ST. LOUIS, MO – October 27, 2021) – Curi received a Study May Proceed letter from th begin its Phase 3 trial with its investigational radiopharmaceutical that binds to the Prostat protein. Curium is working closely with sites Multi-Center, Open-Label, Randomized Phas 177Lu-PSMA-I&T versus Hormone Therapy Prostate Cancer).

If approved, Curium expects to manufacture leveraging its centralized production capabili advancing Lu 177 PSMA I&T to the clinical t announcement for our Cu 64 PSMA I&T ima opportunity for patients nationwide and their America, Mike Patterson.

"We are committed to working closely with th radiopharmaceutical agent to patients and th President of Medical and Compliance, Ed Po additional clinical trial sites as we finalize our

About Curium

Curium is the world's largest nuclear medicin distribute world-class radiopharmaceutical pr proven heritage combined with a pioneering excellence, and unparalleled service.

With manufacturing facilities across Europe PET and therapeutic radiopharmaceutical so over 14 million patients annually. The name radioactive researchers Marie and Pierre Cu named and emphasizes our focus on nuclea

To learn more, visit www.curiumpharma.com please contact Janet Ryan, media contact fo

CURIUM™
LIFE FORWARD

FOR IMMEDIATE RELEASE **January, 25th 2022**

Curium to become major player in the supply on non carrier added Lu-177

(London – 25/01/2022) – Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added Lutetium 177. Curium also announced it will be funding the associated capital investment to build a production facility of 15000 Ci per annum on its Petten site in the Netherlands.

Curium's Petten assets are co-located with the world's largest research reactor and the site is already a world leader in the production of reactor based isotopes, the addition of Lutetium 177 will build on this leadership.

Earlier in the year Curium announced the initiation of its ECLIPSE phase three registration trial for its proprietary LuPSMA in the treatment of patients with metastatic castration resistant prostate cancer.

John Sylvester CEO of Curium's SPECT and International businesses commented "this is a major milestone in the Curium's transformation to an oncology therapy company. It builds on our philosophy of reliability of supply being the secret to success in Nuclear Medicine. In addition to serving our internal needs we have the proven global supply chain and sufficient capacity to serve the rapidly growing market for Lu-177 for therapeutic use".

He went on say "We are delighted with Monrol as a technology partner. After extensive benchmarking this technology gave both the highest quality product with the most efficient process. As it is already proven and 'plug and play' in nature, the time to market will be very short".

"Curium's global reach and scale make them ideal partners for our world leading technology, and we are very pleased to announce them as partners" commented Mr. Aydin Kucuk General Manager of Monrol.

Please direct all enquires in the first instance to: ContactLondonHQ@curiumpharma.com

About Curium

Curium is the world's largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.

OTHER RECENT DEVELOPMENTS AT CURIUM



FOR IMMEDIATE

Curium Ann
Drug (IND) A

(ST. LOUIS, MO –
Investigational New
Cu-64 PSMA I&T, a
(PSMA) for use with
metastatic prostate
first Cu-64 PSMA I
of Cu-64's 12.7-hou
its Maryland Height
of Cu-64 would allo
U.S. imaging sites

"We are excited ab
copper-based radio
our recently approv
Patterson. "If appr
prostate cancer ima
flexibility."

"We are committed
radiopharmaceutica
of prostate cancer
Porter. "We look fo
development progra

About Curium

Curium is the world
distribute world-cla
proven heritage co
excellence, and unp

FOR IMMED

Curium I
Investiga

(ST. LOUIS,
received a St
begin its Phas
radiopharmac
protein. Curiu
Multi-Center,
177Lu-PSMA
Prostate Can

If approved, C
leveraging its
advancing Lu
announcemer
opportunity fo
America, Mik

"We are comm
radiopharmac
President of M
additional clin

About Curiu

Curium is the
distribute worl
proven herita
excellence, a

With manufac
PET and ther
over 14 millio
radioactive re
named and e

To learn more
please contac

FOR IMMEDIATE

Curium to be
added Lu-177

(London – 25/01/20
granting access to E
non carrier added Lu
investment to build a
Netherlands.

Curium's Petten ass
already a world lead
will build on this lead

Earlier in the year C
for its proprietary Lut
cancer.

John Sylvester CEO
milestone in the Cu
philosophy of reliabi
serving our internal r
the rapidly growing r

He went on say "
benchmarking this
process. As it is alre

"Curium's global rea
we are very please
Manager of Monrol.

Please direct all enq

About Curium

Curium is the world's
distribute world-class
proven heritage com
excellence and unpa

CURIUM™
LIFE FORWARD

FOR IMMEDIATE RELEASE April 5, 2022

Curium Announces FDA Approval of a Generic Version of DaTscan™ (Ioflupane I 123 Injection) in the U.S.

(St. Louis, MO – April 5, 2022) - Curium announced today that its generic version of DaTscan (Ioflupane I 123 Injection) was approved on March 30, 2022, by the U.S. Food and Drug Administration (FDA). Ioflupane I 123 Injection is a single-photon emission computed tomography (SPECT) brain imaging agent used to assist in the evaluation of adult patients with suspected Parkinsonian Syndromes. Curium has begun accepting customer orders for fulfillment beginning Monday, April 11.

"The number of patients being diagnosed with Parkinsonian Syndromes is, unfortunately, growing. Approximately 1% of the population over the age of 65 are affected and that population is increasing. The addition of Curium's generic Ioflupane I 123 Injection to the market will offer appropriate patients an opportunity to be scanned Monday through Thursday early in the morning." said Michael Patterson, Curium's North American CEO. "Providing hospitals and imaging centers the opportunity to scan patients on a day or at a time not currently available offers flexibility when scheduling this important study."

"Ioflupane I 123 Injection is an important tool many neurologists and movement disorder specialists use when diagnosing adult patients with suspected Parkinsonian Syndromes," said Ed Porter, North American Vice President of Medical and Compliance. "Over the past two years Curium has introduced several new products, both branded and generic, which help physicians diagnose patients. We are thrilled to add Ioflupane I 123 Injection to that growing list of medicines to help patients move life forward."

DaTscan™ is a registered trademark of GE Healthcare Limited.

About Ioflupane I 123 Injection

INDICATIONS AND USAGE
Ioflupane I 123 Injection is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS). In these patients, Ioflupane I 123 Injection may be used to help differentiate essential tremor from tremor due to PS (idiopathic Parkinson's disease, multiple system atrophy and progressive supranuclear palsy). Ioflupane I 123 Injection is an adjunct to other diagnostic evaluations.

Ioflupane I 123 Injection was not designed to distinguish among PD, MSA, and PSP. The effectiveness of Ioflupane I 123 Injection as a screening or confirmatory test and for monitoring disease progression or response to therapy has not been established.

OTHER RECENT DEVELOPMENTS AT CURIUM



FOR IMMEDIATE

Curium Anno
Drug (IND) A

(ST. LOUIS, MO –
Investigational New
Cu-64 PSMA I&T, a
(PSMA) for use with
metastatic prostate
first Cu-64 PSMA I
of Cu-64's 12.7-hou
its Maryland Height
of Cu-64 would allo
U.S. imaging sites

"We are excited ab
copper-based radio
our recently approv
Patterson. "If appr
prostate cancer ima
flexibility."

"We are committed
radiopharmaceutica
of prostate cancer
Porter. "We look fo
development progr

About Curium

Curium is the world
distribute world-cla
proven heritage co
excellence, and un

FOR IMMED

Curium I
Investiga

(ST. LOUIS,
received a St
begin its Phas
radiopharmac
protein. Curiu
Multi-Center,
177Lu-PSMA
Prostate Can

If approved, C
leveraging its
advancing Lu
announcemer
opportunity fo
America, Mike

"We are comm
radiopharmac
President of M
additional clin

About Curiu

Curium is the
distribute worl
proven herita
excellence, a

With manufac
PET and ther
over 14 millio
radioactive re
named and e

To learn more
please contac

FOR IMMED

Curium t
added Lu

(London – 25
granting acce
non carrier ad
investment to
Netherlands.

Curium's Pett
already a worl
will build on th

Earlier in the
for its proprieta
cancer.

John Sylveste
milestone in
philosophy of
serving our int
the rapidly gro

He went on
benchmarking
process. As it

"Curium's glob
we are very
Manager of M

Please direct

About Curiu

Curium is the
distribute worl
proven heritag
excellence an

FOR IMMEDIATE RELE

Curium Annou
Version of DaT
U.S.

(St. Louis, MO – April 5,
(Ioflupane I 123 Injection)
Administration (FDA). Iof
tomography (SPECT) bra
suspected Parkinsonian
fulfillment beginning Mon

"The number of patients
growing. Approximately
population is increasing.
market will offer appropri
early in the morning." sai
hospitals and imaging ce
currently available offers

"Ioflupane I 123 Injection
specialists use when diag
Ed Porter, North America
Curium has introduced s
diagnose patients. We ar
medicines to help patient

DaTscan™ is a registered

About Ioflupane I 123 In

INDICATIONS AND USA
Ioflupane I 123 Injection i
visualization using single
assist in the evaluation o
these patients, Ioflupane
from tremor due to PS (id
progressive supranuclear
evaluations.

Ioflupane I 123 Injection
effectiveness of Ioflupane
disease progression or re

CURIUM™
LIFE FORWARD

FOR IMMEDIATE RELEASE **April 19, 2022**

Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

(St. Louis, MO – April 19, 2022) - Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now be offering 50% more doses for patient use Monday-Friday beginning the week of May 1, 2022.

"We are incredibly pleased with the overwhelming response to Detectnet that has warranted an increase in production. Further, we are proud of the dedication of all the Curium employees who worked so diligently to support this effort. We now feel confident in our ability to service the entire adult neuroendocrine market, who may require a somatostatin receptor PET scan." said Curium CEO of North America, Michael Patterson. "At Curium, we are focused on redefining the experience of cancer through our trusted legacy in nuclear medicine. Today's announcement further demonstrates our commitment to the physicians and patients in the neuroendocrine cancer community."

"Neuroendocrine cancer continues to be a priority focus for Curium," said Michael Wessler, Senior Director of Marketing. "We are very pleased with this increase in commercial capacity and are excited Detectnet will be even more accessible. Having the high accuracy of Detectnet readily available to patients and their physicians can help determine the best treatment plan."

About Detectnet

INDICATIONS AND USAGE

Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients.

IMPORTANT RISK INFORMATION

WARNINGS AND PRECAUTIONS

Radiation Risk

Diagnostic radiopharmaceuticals, including Detectnet, contribute to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling and preparation procedures to protect patients and health care workers from unintentional radiation exposure. Advise patients to hydrate before and after administration and to void frequently after administration.

Hypersensitivity Reactions

Hypersensitivity reactions following administration of somatostatin receptor imaging agents predominantly consisted of cutaneous reactions such as rash and pruritis. Reactions reversed either spontaneously or with routine symptomatic management. Less frequently hypersensitivity reactions included angioedema or cases with features of anaphylaxis.

OTHER RECENT DEVELOPMENTS AT CURIUM



FOR IMMEDIATE

**Curium Ann
Drug (IND) A**

(ST. LOUIS, MO –
Investigational New
Cu-64 PSMA I&T, a
(PSMA) for use with
metastatic prostate
first Cu-64 PSMA I
of Cu-64's 12.7-hou
its Maryland Height
of Cu-64 would allo
U.S. imaging sites

"We are excited ab
copper-based radio
our recently approv
Patterson. "If appr
prostate cancer ima
flexibility."

"We are committed
radiopharmaceutica
of prostate cancer
Porter. "We look fo
development progra

About Curium

Curium is the world
distribute world-cla
proven heritage co
excellence, and unp

FOR IMMED

**Curium I
Investiga**

(ST. LOUIS,
received a St
begin its Phas
radiopharmac
protein. Curiu
Multi-Center,
177Lu-PSMA
Prostate Can

If approved, C
leveraging its
advancing Lu
announcemer
opportunity fo
America, Mike

"We are comm
radiopharmac
President of M
additional clin

About Curiu

Curium is the
distribute worl
proven heritag
excellence, a

With manufac
PET and ther
over 14 millio
radioactive re
named and er

To learn more
please contac

FOR IMMED

**Curium t
added Lu**

(London – 25
granting acce
non carrier ad
investment to
Netherlands.

Curium's Pett
already a worl
will build on th

Earlier in the
for its proprieta
cancer.

John Sylveste
milestone in t
philosophy of
serving our int
the rapidly gro

He went on
benchmarking
process. As it

"Curium's glob
we are very
Manager of M

Please direct

About Curiu

Curium is the
distribute worl
proven heritag
excellence an

FOR IMME

**Curium
Versio
U.S.**

(St. Louis,
(Ioflupane I
Administrati
tomography
suspected P
fulfillment be

"The numbe
growing. Ap
population i
market will
early in the
hospitals an
currently av

"Ioflupane I
specialists u
Ed Porter, N
Curium has
diagnose pa
medicines t

DaTscan™ i

About Ioflu

INDICATIO
Ioflupane I 1
visualization
assist in the
these patien
from tremor
progressive
evaluations.

Ioflupane I 1
effectivenes
disease pro

FOR IMMEDIATE RELEASE

**Curium Announces Signific
(copper Cu 64 dotatate inje**

(St. Louis, MO – April 19, 2022) - Curium anno
capacity of Detectnet to accommodate the signif
offering 50% more doses for patient use Monda

"We are incredibly pleased with the overwhelmir
increase in production. Further, we are proud of
worked so diligently to support this effort. We n
neuroendocrine market, who may require a som
North America, Michael Patterson. "At Curium,
through our trusted legacy in nuclear medicine.
commitment to the physicians and patients in th

"Neuroendocrine cancer continues to be a priorit
Director of Marketing. "We are very pleased with
Detectnet will be even more accessible. Having
patients and their physicians can help determine

About Detectnet
INDICATIONS AND USAGE
Detectnet is indicated for use with positron emis
receptor positive neuroendocrine tumors (NETs)

IMPORTANT RISK INFORMATION

WARNINGS AND PRECAUTIONS

Radiation Risk
Diagnostic radiopharmaceuticals, including Dete
radiation exposure. Long-term cumulative radiat
Ensure safe handling and preparation procedure
unintentional radiation exposure. Advise patients
frequently after administration.
Hypersensitivity Reactions
Hypersensitivity reactions following administratic
consisted of cutaneous reactions such as rash a
with routine symptomatic management. Less fre
cases with features of anaphylaxis.

FOR IMMEDIATE RELEASE May 3, 2022

Curium's Phase 3 ECLIPSE Trial Starts Enrolling Patients

(St. Louis, MO – May 3, 2022) - Curium announced today it has successfully enrolled and dosed patients in the ECLIPSE Trial. ECLIPSE is a Phase 3, multi-center, open-label, randomized clinical trial comparing the safety and efficacy of 177Lu-PSMA-I&T versus standard of care hormone therapy in patients with metastatic castration-resistant prostate cancer. The clinical trial is enrolling patients at sites across the U.S. and will be opening clinical trial sites in Europe in 2022.

"We are thrilled to see the ECLIPSE clinical trial progress with patients enrolled and treated with 177Lu-PSMA-I&T," said Renaud Dehareng, Curium's Group CEO. "We are dedicated to redefining the experience of cancer through our trusted legacy in nuclear medicine. The ECLIPSE clinical trial demonstrates our commitment to patients with metastatic castration-resistant prostate cancer in North America and Europe."

"We would like to thank the investigators and healthcare providers at the clinical trial sites for their dedication to patients with metastatic castration-resistant prostate cancer," said Sakir Mutevelic, MD, Curium's Chief Medical Officer. "Through our collaboration, we are working together to determine the safety and efficacy of this potential new investigational treatment for patients in need."

For more information about the ECLIPSE Trial, visit Curium's Clinical Trial website https://www.curiumpharma.com/clinical-trials/ or contact Curium's Clinical Trial team directly at ECLIPSE@curiumpharma.com with questions or to locate a clinical trial site near you.

About Curium

Curium is the world's largest nuclear medicine company. We develop, manufacture and distribute world-class radiopharmaceutical products to help patients around the globe. Our proven heritage combined with a pioneering approach are the hallmarks to deliver innovation, excellence and unparalleled service.

With manufacturing facilities across Europe and the United States, Curium delivers SPECT, PET and therapeutic radiopharmaceutical solutions for life-threatening diseases to over 14 million patients annually. The name 'Curium' honors the legacy of pioneering radioactive materials researchers Marie and Pierre Curie, after whom the radioactive element curium was named and emphasizes our focus on nuclear medicine. To learn more, visit curiumpharma.com.

For more information about this press release, please contact Sandy Borgschulte sandy.borgschulte@curiumpharma.com or 314.954.6637.

CURRENT Mo-99 SUPPLY OUTLOOK

- Curium has increased the number of Mo-99 production runs in Petten and the output from each run.
- We have also increased the amount of contracted *Outage Reserve Capacity* at the reactors we use to create even more reliability for Curium Mo-99 production.
- Curium routinely increases Mo-99 production during periods of anticipated and unanticipated Mo-99 shortages to ensure patients are able get the Tc-99m they need.
- As demand for Mo-99 continues to grow as we emerge from COVID-19, Curium will be prepared to meet the supply challenges.

BRIEF HFR OUTAGE IN JANUARY

- During a re-start of the HFR in January operators identified a technical defect in the cooling system and did not re-start the reactor on schedule.
- The defect was determined to be a water leak outside the core, and NRG immediately began inspections and preparations to restore the system.
- The BR2 and MARIA reactors were able to modify their production schedules to allow for additional Mo-99 production, eliminating any significant shortages.
- The Dutch regulator approved the repairs and gave the green light to re-start the reactor on Mar 9 and HFR was back up to full power on Mar 17.



HFR reactor core

MINIMIZING THE IMPACT OF RUSSIAN NUCLEAR SANCTIONS ON Mo-99 PRODUCTION

- None of Curium's LEU for Mo-99/Xe-133 target production is sourced from Russia.
- Only one of the three reactors Curium uses for Mo-99/Xe-133 production is totally reliant on Russian supplied LEU for their fuel. That reactor has sufficient LEU fuel in-house to last until at least 2025. We continue to monitor this situation with the reactors we use for Mo-99/Xe-133 production.
- Curium and CORAR (The Council on Radionuclides & Radiopharmaceuticals) continue to work with the Office of Foreign Asset Control (OFAC – State Department) so there are aware of the industry's reliance on Russia for LEU, as well as enriched stable isotopes and other radionuclides.
- NMEU (Nuclear Medicine – Europe) is also working with the EU Parliament to ensure they are aware of the industry's need for these material sourced from Russia.
- So far, these efforts have proven effective in preventing any impact to Mo-99 or Xe-133 production.

LONG TERM SUPPLY OF HA LEU

- Curium remains concerned about the long-term supply of HA LEU for Mo-99/Xe-13/I-131 production.
- Curium and CORAR have been in regular communication with DOE about ensuring the continued supply of HA LEU for medical isotope production.
- Now that the industry is largely converted to LEU for production of medical isotopes the need for HA LEU is greater than ever.
- Our industry's need will be competing with the advanced reactor designs' need for HA LEU.
- It is incumbent on DOE that they help facilitate production methodologies and the start-up of commercial production of HA LEU before current stock is depleted.
- We have been assured by DOE they are aware of our needs and are addressing this issue.

SUMMARY

- Curium's LEU conversion for Mo-99 was fully achieved in early January of 2018, and Xe-133 in May of 2018.
- We have established arrangements with a diverse network of reactors to irradiate targets for our Mo-99 production process and are working with new reactors to develop that capability.
- Curium has taken steps to steadily increase reliability and capacity of Mo-99 production to meet market demands, including periods of Mo-99 shortages.
- The HFR outage in early 2022 demonstrated the effectiveness of the reactors working together to back each other up.
- Curium and the industry's efforts to-date have minimized any impact on current or planned Russian nuclear sanctions on Mo-99/Xe-133 production.
- The industry is relying on DOE to develop production methodologies for new production of HA LEU for our industry.